论文标题
对基于图像的原代黑色素瘤分类为基因组免疫亚组的弱监督学习
Weakly-supervised learning for image-based classification of primary melanomas into genomic immune subgroups
论文作者
论文摘要
确定早期预后标志物和对患者进行有效治疗的分层是改善黑色素瘤患者预后的两个关键挑战。先前的研究已使用肿瘤转录组数据将患者分类为免疫亚组,这些亚组与差异性黑色素瘤特异性生存和潜在治疗策略有关。但是,获取转录组数据是一个耗时且昂贵的过程。此外,它通常不在当前的临床工作流程中使用。在这里,我们试图通过开发深度学习模型来克服这一点,以将吉普吉像H&E染色的病理幻灯片分类为临床工作流程,并在这些免疫亚组中良好确定。以前的亚型方法已经采用了有监督的学习,需要完全注释的数据,或者仅检查了黑色素瘤患者中的单个遗传突变。我们利用一种多种现实的学习方法,该方法仅需要幻灯片级标签,并使用注意机制来突出对分类非常重要的区域。此外,我们表明,与病理 - 敏锐的模型相比,特定于病理学的自我监督模型可产生更好的表示,以改善我们的模型性能,以将组织病理学图像分类为高或低免疫亚组的平均AUC为0.76。我们预计这种方法可能会使我们能够找到高重要性的新生物标志物,并可以作为临床医生推断肿瘤的免疫景观并对患者进行分层的工具,而无需进行额外的昂贵遗传测试。
Determining early-stage prognostic markers and stratifying patients for effective treatment are two key challenges for improving outcomes for melanoma patients. Previous studies have used tumour transcriptome data to stratify patients into immune subgroups, which were associated with differential melanoma specific survival and potential treatment strategies. However, acquiring transcriptome data is a time-consuming and costly process. Moreover, it is not routinely used in the current clinical workflow. Here we attempt to overcome this by developing deep learning models to classify gigapixel H&E stained pathology slides, which are well established in clinical workflows, into these immune subgroups. Previous subtyping approaches have employed supervised learning which requires fully annotated data, or have only examined single genetic mutations in melanoma patients. We leverage a multiple-instance learning approach, which only requires slide-level labels and uses an attention mechanism to highlight regions of high importance to the classification. Moreover, we show that pathology-specific self-supervised models generate better representations compared to pathology-agnostic models for improving our model performance, achieving a mean AUC of 0.76 for classifying histopathology images as high or low immune subgroups. We anticipate that this method may allow us to find new biomarkers of high importance and could act as a tool for clinicians to infer the immune landscape of tumours and stratify patients, without needing to carry out additional expensive genetic tests.